# CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome

> **NCT05617625** · PHASE2 · SUSPENDED · sponsor: **Guenther Koehne** · enrollment: 50 (estimated)

## Conditions studied

- Myelodysplastic Syndromes
- Graft Vs Host Disease
- Graft-versus-host-disease

## Interventions

- **DRUG:** Busulfan
- **DRUG:** Melphalan
- **DRUG:** Fludarabine
- **DEVICE:** CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)

## Key facts

- **NCT ID:** NCT05617625
- **Lead sponsor:** Guenther Koehne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2026-06
- **Primary completion:** 2033-06
- **Final completion:** 2033-06
- **Target enrollment:** 50 (ESTIMATED)
- **Why stopped:** The study has been put on hold while pending CMS approval
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05617625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05617625, "CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05617625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*